Eli Lilly Gains 54% On 56% Revenue Surge and New Obesity Pill Approval
MRK•Eli Lilly’s shares have surged 54% over nine months, driven by 56% year-over-year revenue growth and a 47.3% operating margin, fueled by $12.8 billion in quarterly Mounjaro and Zepbound sales. The company secured FDA approval for oral obesity pill Foundayo and agreed to acquire Orna Therapeutics and Centessa Pharmaceuticals.
1. Stock Revaluation on Growth Surge
Shares have climbed 54% over nine months relative to a 15% S&P 500 return, indicating a fundamental market repricing rather than a temporary bounce.
2. Revenue and Margin Expansion
In its latest quarter, Eli Lilly delivered 56% year-over-year revenue growth and a 47.3% operating margin, with Mounjaro and Zepbound generating $12.8 billion in sales.
3. Foundayo Approval Opens New Market
The FDA approval of Foundayo marks the first oral incretin launched with an obesity indication, positioning Lilly to capture a significant weight management market.
4. Strategic Acquisitions to Bolster Pipeline
Lilly announced acquisitions of Orna Therapeutics and Centessa Pharmaceuticals, signaling plans to reinvest current cash flows into next-generation drug development.
